Literature DB >> 15589001

Clinical characteristics of persistent lone atrial fibrillation in the RACE study.

Michiel Rienstra1, Vincent E Hagens, Dirk J Van Veldhuisen, Hans A Bosker, Jan G P Tijssen, Otto Kamp, Jelte Bouma, Nic J G M Veeger, Harry J G M Crijns, Isabelle C Van Gelder.   

Abstract

In the RAte Control versus Electrical cardioversion for persistent atrial fibrillation (RACE) study, 522 patients were randomized to either rate or rhythm control therapy. Lone atrial fibrillation (AF) was present in 89 patients. Demographics, cardiovascular mortality and morbidity, and quality of life were compared between patients with lone AF and those with underlying structural heart disease. Patients with lone AF were significantly younger (65 +/- 10 vs 69 +/- 8 years) and had fewer complaints of fatigue (p = 0.01) and dyspnea (p = 0.005). With lone AF, quality-of-life scores were higher on almost all 8 Medical Outcomes Study Short-Form health survey questionnaire subscales, and comparable to healthy, age- and gender-matched controls. Mean follow-up was 2.3 +/- 0.6 years. Cardiovascular end points occurred in 9 patients with lone AF (10%), consisting of death (all bleedings) 3%, thromboembolic complications in 3%, nonfatal bleeding in 2%, and pacemaker implantation in 2%, but no heart failure and severe adverse effects due to antiarrhythmic drugs occurred. End points occurred in 95 patients (22%) with underlying diseases. Heart failure and severe adverse effects from drugs did not occur in patients with lone AF in this study. Despite the absence of demonstrable cardiovascular and cerebrovascular disease, lone AF is associated with bleeding and thromboembolism.

Entities:  

Mesh:

Year:  2004        PMID: 15589001     DOI: 10.1016/j.amjcard.2004.08.024

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

Review 2.  Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy.

Authors:  Babar Parvez; Dawood Darbar
Journal:  J Atr Fibrillation       Date:  2010-06-01

3.  The Importance of Atrial Fibrillation's Associated Comorbidities as Clinical Presentation and Outcome Contributors.

Authors:  James A Reiffel
Journal:  J Atr Fibrillation       Date:  2021-08-31

4.  Inhibition of Adenosine Pathway Alters Atrial Electrophysiology and Prevents Atrial Fibrillation.

Authors:  Luca Soattin; Anniek Frederike Lubberding; Bo Hjorth Bentzen; Torsten Christ; Thomas Jespersen
Journal:  Front Physiol       Date:  2020-06-12       Impact factor: 4.566

Review 5.  Dyspnea in patients with atrial fibrillation: Mechanisms, assessment and an interdisciplinary and integrated care approach.

Authors:  Rachel M J van der Velden; Astrid N L Hermans; Nikki A H A Pluymaekers; Monika Gawalko; Adrian Elliott; Jeroen M Hendriks; Frits M E Franssen; Annelies M Slats; Vanessa P M van Empel; Isabelle C Van Gelder; Dick H J Thijssen; Thijs M H Eijsvogels; Carsten Leue; Harry J G M Crijns; Dominik Linz; Sami O Simons
Journal:  Int J Cardiol Heart Vasc       Date:  2022-07-19

6.  Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Jared W Magnani; Faye L Norby; Sunil K Agarwal; Elsayed Z Soliman; Lin Y Chen; Laura R Loehr; Alvaro Alonso
Journal:  JAMA Cardiol       Date:  2016-07-01       Impact factor: 14.676

Review 7.  The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis.

Authors:  Naqash J Sethi; Joshua Feinberg; Emil E Nielsen; Sanam Safi; Christian Gluud; Janus C Jakobsen
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.